Skip Nav Destination
A phase 2 study of obinutuzumab combined with lenalidomide in previously untreated high tumor burden follicular lymphoma
Evaluation of in vivo CAR transgene levels in tisagenlecleucel-treated patients with relapsed/refractory B-ALL and DLBCL
Circulating tumor DNA determinants of response and outcome in relapsed/refractory mantle cell lymphoma
The efficacy of rosuvastatin to reduce circulating tissue factor extracellular vesicles after ovarian cancer surgery
Issue Archive
September 9 2025
In this Issue
Table of Contents
INSIDE BLOOD ADVANCES
ADVANCES VIEWPOINT
REVIEW ARTICLE
Up-front alternative donor HCT in severe aplastic anemia: gaps and opportunities to translate evidence into practice
Neel S. Bhatt,Azra Borogovac,Yvonne A. Efebera,Anna DeSalvo,Steven M. Devine,Amy Foley,Valerie Greco-Stewart,Betty K. Hamilton,Mykala Heuer,Todd Molfenter,John P. Plastaras,Brittany K. Ragon,Sarah A. Wall,Larisa Broglie,Mark B. Juckett,Nandita Khera,Mary M. Horowitz,Amy E. DeZern
CLINICAL TRIALS AND OBSERVATIONS
A phase 2 study of obinutuzumab combined with lenalidomide in previously untreated high tumor burden follicular lymphoma
Clinical Trials & Observations
Neha Akkad,Lei Feng,Jason R. Westin,Fredrick B. Hagemeister,Hun Ju Lee,Luis Fayad,Sairah Ahmed,Ranjit Nair,Maria Alma Rodriguez,Paolo Strati,Dai Chihara,Christopher R. Flowers,Linda Claret,Karina Ibanez,Michael Wang,Nathan H. Fowler,Jared Henderson,R. Eric Davis,Sattva S. Neelapu,Michael Green,Loretta J. Nastoupil
Evaluation of in vivo CAR transgene levels in tisagenlecleucel-treated patients with relapsed/refractory B-ALL and DLBCL
Clinical Trials & Observations
Rakesh Awasthi,Stephan A. Grupp,Edward R. Waldron,Gregory A. Yanik,Constantine S. Tam,Susana Rives,Joseph P. McGuirk,Michael A. Pulsipher,Ulrich Jaeger,Gary D. Myers,Peter Borchmann,Stephen J. Schuster,Heather E. Stefanski,Michael R. Bishop,Abhijit Chakraborty,Aisha Masood,André Baruchel,Edmund K. Waller
HEALTH SERVICES AND OUTCOMES
HEMATOPOIESIS AND STEM CELLS
LYMPHOID NEOPLASIA
BRCA1/2 impact on the development of implant-associated lymphoma in women with breast cancer and textured implants
Paola Ghione,Diana Mandelker,Maria Arcila,Venkatraman Seshan,Mary Beth Terry,Joseph Vijai,Peter Cordeiro,Chad Vanderbilt,Joyce Pressley,Alexander Chan,Natasha Galasso,Ahmet Dogan,Gilles Salles,Daphne de Jong,Flora van Leeuwen,Steven Horwitz
The OHI index predicts early mortality from organ dysfunction and survival benefit from etoposide in patients with lymphoma
Adi Zoref-Lorenz,Jun Murakami,Ronit Gurion,Swaminathan P. Iyer,Uri Abadi,Inbar Cohen,Gaurav Goyal,Shehab Mohamed,Sarah Nikiforow,Abd El Haleem Natour,Shiri Weinstein,Joanne Yacobovich,Hae Lin Cho,Pia Raanani,Arnon Nagler,Nancy Berliner,Naval Daver,Gilad Itchaki,Shai Izraeli,Martin Ellis,Michael B. Jordan
Circulating tumor DNA determinants of response and outcome in relapsed/refractory mantle cell lymphoma
Clinical Trials & Observations
Leo Meriranta,Rasmus Rask Kragh Jørgensen,Annika Pasanen,Arne Kolstad,Martin Hutchings,Carsten Utoft Niemann,Tarec Christoffer El-Galaly,Jon Riise,Jacob Haaber Christensen,Kristina Sonnevi,Lone Bredo Pedersen,Karin Fahl Wader,Ingrid Glimelius,Sirpa Leppä,Mats Jerkeman
MYELOID NEOPLASIA
PLASMA CELL DISORDERS
Prognostic impact of focal lesion location and persistence in multiple myeloma: insights from serial PET/DWI imaging
Carolina Schinke,Leo Rasche,Cody Ashby,Rudy van Hemert,Sharmilan Thanendrarajan,Samer Al Hadidi,Maurizio Zangari,Clyde Bailey,Daisy V. Alapat,John D. Shaughnessy, Jr,Fenghuang Zhan,Bart Barlogie,Frits van Rhee,Niels Weinhold
PLATELETS AND THROMBOPOIESIS
RED CELLS, IRON, AND ERYTHROPOIESIS
TRANSFUSION MEDICINE
TRANSPLANTATION
Impact of shared HLA determinants between patient and losing cord blood unit on relapse after double cord blood transplantation
Robert Wynn,Fernanda Volt,Philippe Guardiola,Srividhya Senthil,Graziana Scigliuolo,Chantal Kenzey,Barbara Cappelli,Annalisa Ruggeri,Ryad Tamouza,Vanderson Rocha,Chloe Anthias,Régis Peffault de la Tour,Katherine Clesham,Anna Castleton,Michel Schaap,Persis Amrolia,Marc Bierings,Jan J. Cornelissen,Kay Poulton,Eliane Gluckman
RESEARCH LETTERS
Patterns of progression among 427 patients with smoldering myeloma diagnosed after 2014: importance of monitoring
Efstathios Kastritis,Irene Solia,Panagiotis Malandrakis,Foteini Theodorakakou,Ioannis Ntanasis-Stathopoulos,Nikolaos Kanellias,Despina Fotiou,Magdalini Migkou,Evangelos Eleutherakis-Papaiakovou,Vassiliki Spiliopoulou,Nikoleta Kokkali,Asimina Papanikolaou,Stavroula Giannouli,Maria Gavriatopoulou,Evangelos Terpos,Meletios A. Dimopoulos
The efficacy of rosuvastatin to reduce circulating tissue factor extracellular vesicles after ovarian cancer surgery
Clinical Trials & Observations
Soravis Osataphan,Rushad Patell,Mrigya Babuta,Rachel P. Rosovsky,Yohei Hisada,Charly Edmiston,Pavania Elavalakanar,Michael A. Pfeffer,Amy Bregar,Amanda Ramos,Leslie Garrett,Siyang Ren,Donna Neuberg,Gyongyi Szabo,Robert Flaumenhaft,Nigel Mackman,Meghan Shea,Jeffrey I. Zwicker
COMMENTARY
-
Cover Image
Cover Image
Illustration of the roles of PROSER1 and TET2 in the regulation of DNA methylation and hematopoiesis. PROSER1 is a pan-TET interactor important for maintenance of DNA methylation homeostasis in hematopoietic cells. Loss of PROSER1 results in disruption of TOPD (TET-OGT-PROSER1-DBHS) complexes and overlapping and distinct enhancer DNA methylation changes compared to changes observed in TET2 knockout cells. These DNA methylation changes and the resulting deregulation of genes governing cell cycle and hematopoietic stem cells (HSCs) likely drive the observed exhaustion of HSC activity over time. See the article by Knatko et al.
Advertisement intended for health care professionals
Advertisement intended for health care professionals
Reality bites: allocating gene therapy for hemoglobinopathies